Detail of the clinical trial

Title of the trial A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
EudraCT number 2019-004023-20
Protocol number MK-3475-992
Sponsor Merck Sharp & Dohme Corp., One Merck Drive, Whitehouse Station, New Jersey,08889, United States of America
Indications Oncology
Diagnosis Bladder Cancer
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 23.3.2020
Date of approval by EC 8.1.2020
Date of initiation CT in ČR
Date of ending CT in ČR
Sites Nemocnice Na Bulovce,Ústav radiační onkologie,Budínova 67/2,Praha 8-Libeň,180 81
Fakultní nemocnice v Motole,Onkologická klinika 2. LF UK a FN Motol ,V Úvalu 84,Praha 5-Motol,150 06
Fakultní nemocnice Olomouc,Onkologická klinika,I.P.Pavlova 6,Olomouc,779 00

‹‹ Back to list